Royal Bank of Canada Decreases Stock Holdings in Encompass Health Corporation $EHC

Royal Bank of Canada lowered its position in shares of Encompass Health Corporation (NYSE:EHC) by 23.8% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 78,697 shares of the company’s stock after selling 24,593 shares during the quarter. Royal Bank of Canada’s holdings in Encompass Health were worth $7,612,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. raised its stake in shares of Encompass Health by 3,059,159.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock valued at $402,640,000 after acquiring an additional 3,793,358 shares during the last quarter. Norges Bank purchased a new position in Encompass Health during the 4th quarter valued at about $133,221,000. Price T Rowe Associates Inc. MD raised its position in Encompass Health by 24.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,805,413 shares of the company’s stock valued at $510,047,000 after purchasing an additional 948,202 shares during the last quarter. Millennium Management LLC lifted its holdings in Encompass Health by 140.0% in the 3rd quarter. Millennium Management LLC now owns 1,223,665 shares of the company’s stock worth $155,430,000 after buying an additional 713,738 shares during the period. Finally, 8 Knots Management LLC bought a new stake in shares of Encompass Health in the 2nd quarter worth approximately $78,644,000. Institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Performance

Shares of EHC stock opened at $125.78 on Tuesday. The company’s fifty day moving average price is $107.37 and its 200-day moving average price is $104.81. The stock has a market cap of $12.48 billion, a PE ratio of 20.49, a price-to-earnings-growth ratio of 2.52 and a beta of 0.72. The company has a current ratio of 1.19, a quick ratio of 1.17 and a debt-to-equity ratio of 0.76. Encompass Health Corporation has a 12 month low of $92.77 and a 12 month high of $127.99.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.48 by $0.07. Encompass Health had a net margin of 10.01% and a return on equity of 18.08%. The company had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period last year, the business earned $1.40 EPS. Encompass Health’s quarterly revenue was up 9.6% compared to the same quarter last year. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. On average, equities analysts expect that Encompass Health Corporation will post 6.07 EPS for the current fiscal year.

Encompass Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be issued a dividend of $0.21 per share. The ex-dividend date is Thursday, October 1st. This is a positive change from Encompass Health’s previous quarterly dividend of $0.19. This represents a $0.84 annualized dividend and a dividend yield of 0.7%. Encompass Health’s dividend payout ratio (DPR) is 12.38%.

Wall Street Analysts Forecast Growth

EHC has been the subject of a number of recent analyst reports. Leerink Partners set a $152.00 target price on Encompass Health in a report on Friday, May 22nd. Weiss Ratings cut shares of Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, June 26th. Truist Financial boosted their price objective on shares of Encompass Health from $140.00 to $150.00 and gave the company a “buy” rating in a research report on Friday. Wall Street Zen cut shares of Encompass Health from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, UBS Group lifted their target price on shares of Encompass Health from $150.00 to $155.00 and gave the company a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Encompass Health has a consensus rating of “Moderate Buy” and a consensus price target of $148.71.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post?acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end?of?life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.